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Organ transplantation is the treatment of choice for 
patients with end-stage organ failure. Most of them 
will require lifelong immunosuppression to prevent 
both acute and chronic rejection. According to the 
Organ Donor Foundation (http://www.odf.org.za), 
in 2013, 335 solid organ transplants (SOTs) were performed in 
South Africa (SA). The majority of these were kidney transplants, 
followed by heart, liver, pancreas and lung transplants. As 
there are few dedicated transplant centres in SA, physicians 
and general practitioners are often the primary caregivers and 
manage transplant recipients as part of shared care with the 
transplant centre. It is hoped that this review provides insight 
into the mechanisms of tolerance and the immunosuppressive 
armamentarium.
T-cell recognition of the allograft major histocompatibility complex 
antigens is the central event initiating cellular rejection of the allograft, 
and subsequent full T-cell activation requires three signals (Fig. 1).[1,2] 
Immunosuppressive regimens currently used in clinical practice 
are nonspecific and target T-cell activation, clonal expansion or 
differentiation into effector T cells. While these therapeutic regimens 
have advanced considerably and one-year graft survival figures for 
most SOTs are >90%, long-term graft survival remains poor owing 
to graft loss from chronic rejection. These immunosuppressive drugs 
are also associated with significant long-term side-effects, such as 
opportunistic infections, malignancies, nephrotoxicity, hypertension 
and diabetes mellitus. Experimental models suggest that induction of 
tolerance can prevent chronic rejection.
Transplantation tolerance 
The ‘holy grail’ of SOT is therefore the development of a permanent 
specific immune tolerance against donor allogeneic antigens without 
the long-term use of immunosuppression.[2] Clinically, this is known 
as operational tolerance and is defined as a well-functioning graft 
lacking histological signs of acute or chronic rejection in the absence 
of immunosuppression for at least one year in an immunocompetent 
person capable of responding to infections.[3-5]
However, operational tolerance occurs infrequently and is difficult 
to predict, and incidence varies by allograft type. It occurs in up to 
20% of liver transplant recipients and is much less common in renal 
transplant recipients, with only isolated case reports of operational 
tolerance in lung and heart transplant recipients.[3-6] 
Although the liver is an immunologically privileged organ, 
operational tolerance is still difficult to achieve shortly after 
transplantation, but becomes increasingly frequent during the 
second decade of transplantation.[7] Other clinical factors favouring 
operational tolerance include paediatric transplantation and living-
related liver transplantation.[6,7] 
Operationally tolerant transplant recipients have been shown to 
exhibit signature transcriptional gene profiles, which differ in liver 
and kidney transplant recipients. Liver transplant recipients express 
a high number of natural killer cell genes, while kidney transplant 
recipients express B-cell regulatory genes. The T regulatory cell 
is a common effector cell, as suggested by an increase in FOXP3 
expression in operationally tolerant recipients.[6,8] 
Clinically operational tolerance can be divided into three groups:[5,6]
• Spontaneous tolerance in patients who have been non-compliant
and discontinued all immunosuppression. 
• Planned weaning under medical supervision to reduce side-effects
and toxicity of immunosuppression.
• Active application of tolerogenic protocols.
Various experimental tolerogenic protocols based on the mechanisms 
of central and peripheral tolerance that normally maintain immune 
homeostasis and self-tolerance have been tested in animal and non-
human primate models, with only a few entering clinical trials and 
clinical practice.[9] Central tolerance results from the clonal deletion of 
self-reactive T cells (death of T cells with T-cell receptors recognising 
host antigens) during maturation in the thymus. Protocols enhancing 
central tolerance are based on attempting to establish chimerism, 
usually microchimerism, which is defined as the presence of donor 
and recipient cell lineages coexisting within the bone marrow of a 
myeloconditioned recipient.[10]
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Peripheral tolerance involves the suppression 
or elimination of self-reactive mature T cells 
in the periphery. This is achieved through 
inactivation of auto-reactive T-cell clones 
by inhibitory molecules or suppression by 
regulatory T cells (Tregs), with the resulting 
T-cell inactivation leading to anergy and 
apoptosis.
Potential protocols enhancing peripheral 
tolerance include:[1,6,11,12]
• Inhibition of alloreactive T-cell responses,
including T-cell-depleting strategies,
co-stimulatory blockade and interleukin
(IL)-2-receptor blockade.
• Inhibition of the humoral response
including B-cell depleting therapies
(rituximab), blockade of B-cell activating
factor (belimumab) and complement
protein C5 (eculizumab) production and
induction of mature plasma cell apoptosis
(bortezomib).
• Anti-cytokine and anti-chemokine thera-
pies preventing homing of activated allo-
reactive T cells to the allograft.
• Enhancement of immune regulatory
mechanisms to inhibit alloreactive T-cell
effector responses via direct ligation or
inhibitory cytokine production. This includes
infusion of tolerogenic immunomodulatory
cells such as expanded regulatory T cells
(Tregs), dendritic cells, macrophages (transplant 
acceptance-inducing cells) and mesenchymal
stromal cells.
Tolerogenic protocols in 
clinical practice
Despite success in animal and non-human 
primate models, very few protocols have 
been successfully used in clinical practice 
and usually not as stand-alone therapy. A 
number of review articles address tolerogenic 
protocols in detail.[1,6,11,12]
Microchimerism. These protocols have 
involved conditioning of the recipient 
with thymic irradiation or total lymphoid 
irradiation plus anti-thymocyte globulin 
(ATG), followed by the infusion of donor 
bone marrow. This also increased the 
number of CD4+ CD25+ Tregs compared 
with CD4 T cells and successfully induced 
tolerance in a small number of kidney 
transplant recipients. 
T-cell depletion. Alemtuzumab (CAM-
PATH-1H), a humanised anti-CD52 mono-
clonal antibody (mAb) that depletes T, B 
and natural killer cells and some monocytes, 
has been shown to reduce the need for 
immunosuppression. Depletion has been 
followed by rapid homeostatic proliferation 
of memory T cells, increased B-cell activating 
factor and alloantibody production and 
therefore this is not a stand-alone therapy. 
Alemtuzumab has been combined with 
rabbit ATG and rapamycin, which has 
the added benefit of inducing Tregs and 
promoting activation-induced cell death of 
effector T cells.
Co-stimulatory blockade . Co-stimulation 
(signal 2) is essential for full T-cell activation 
and differentiation into effector T cells. 
Selective targeting of effector T cells and 
sparing of Tregs are beneficial. The two main 
co-stimulatory pathways are CD28/CTLA-4: 
B7 and the CD154: CD40 pathways.
• CD28/CTLA-4: B7 blockade, i.e. signal 2
blockade. Belatacept – a modified cyto-
toxic T-lymphocyte antigen 4  (CTLA-4) 
immunoglobulin with a high affinity for 
both CD80 (B7-1) and CD86 (B7-2). 
Although combined blocking of CD80 and 
CD86 prevents ligation of CTLA-4 and 
subsequent T-cell activation, this has also 
inhibited the function of Tregs. Increased 
risk of post-transplant lymphoproliferative 
disorders has been documented.
• CD154: CD40 blockade. Administration 
of a humanised anti-CD154 mAb in 
clinical trials has been complicated by the 
development of thromboembolic events.
Immune tolerance remains difficult to achieve 
and disruption of a single pathway is usually 
not sufficient to promote tolerance or long-
term allograft survival. 
Immunosuppression 
in solid organ 
transplantation
Although immune tolerance is desired in 
SOT, we still rely on immunosuppression 
to prevent allograft rejection. Immuno-
suppression has transformed the field of 
SOT since agents were first used over 50 
years ago, and will still be an essential 
component of the armamentarium for the 
foreseeable future.[13,14]
Most SOT recipients need induction 
immunosuppression at the time of 
transplantation (usually an intravenous 
antibody preparation) and maintenance 
Fig. 1. Targets for current immunosuppressive drugs. Signal 1 is delivered through the T-cell receptor 
by recognition of peptide antigens presented in the context of major histocompatibility complex 
molecules on the antigen-presenting cells. This stimulation results in calcineurin activation, a 
process blocked by cyclosporin A or tacrolimus. Activated calcineurin dephosphorylates the nuclear 
factor of activated T cells so that it can enter the nucleus and bind to the interleukin-2 (IL-2) 
promoter. Co-stimulatory signals (signal 2) are necessary for optimal IL-2 gene transcription in 
the T cell. IL-2-receptor stimulation induces the T cell to enter the cell cycle and proliferate (signal 
3); this can be blocked by IL-2-receptor antibodies or by rapamycin, which inhibits signalling 
induced by IL-2-receptor ligation. By blocking purine synthesis, azathioprine and mycophenolate 
mophetil interrupt DNA replication and cell proliferation. (APC = antigen-presenting cells; CYA 
= cyclosporin A; MHC = major histocompatibility complex; MMF = mycophenolate mophetil; 
mTOR = mammalian target of rapamycin; NFAT = nuclear factor of  activated  T cells; TCR = 
T-cell receptor.) (Modified from Golshayan et al.[1])
2 Month 20xx, Vol. xxx, . x
i l l  i l   i  
 li i i  f lf i    ll  
i   i . i  i  i   
i i i  f i  ll l  
 i i i  l l   i   
l   ll  , i   l i  
ll i i i  l i     
i .
i l l  i  i l 
l  i l :[1,6,11,12]
i i i  f ll ti  ll , 
i l i  ll l i  i ,
i l  l   i l i  
 l . 
i i i  f  l 
i l i  ll l i  i
i i , l  f ll i i  
f  li   l
i   li  i   
i i  f  l  ll i  
i .
i i   i i  
i  i  i  f i  ll
i   ll    ll f .
 f i  l
i   i i i  ll i  ll
ff   i  i  li i  
i i i  i  i . i  i l
i f i  f l i  i l
ll     l   ll
, iti  ll ,  t l t
i i  ll   l
l ll .
i   i  i l   
i  l ,  f  l   
 f ll   i  li i l i  
 ll    l  .  
 f i  i l   l i  
l  i  il.[1,6,11,12]
i i i .  l   
i l  i i i  f  i i
i  t i  i i ti   t t l l i  
i i i  l  i  l li
, f ll    i f i  f  
 . i  l  i  
 f     
i    ll   f ll  i  
l  i   ll  f i
l  i i . 
T-cell depletion. Al mtuzumab (CAM
PATH-1H), a humanised an i-CD52 mono-
clonal antibody (mAb) that d pletes T, B 
and natural killer cells and some monocytes, 
has been shown to reduc  the need for
immunosuppression. Depletion has bee
followed by rapid homeostatic prolifer tion 
of memory T cells, increased B-cell activati g 
factor and alloa tibody production nd
therefore this is not a stand-alone therapy. 
Alem uzumab has been ombined with
rabbit ATG and rapamycin, which has
the added benefit of inducing Tregs and 
prom ting activation-induced cell death of 
effector T ce ls.
Co-stimulatory b ockade . Co-stimul ti
(signal 2) is essential for full T- ell activation
and differentiation into effector T cells.
Selective targeting of effector T cells and
sparing of Tregs are beneficial. The two main
co-stimulatory pathways are CD28/CTLA-4:
B7 and the CD154: CD40 pathways.
• CD28/CTLA-4: B7 blockade, .e. signal
2 blockade. Belatac pt – a modified cyto-
toxic T-lymphocyte antigen 4  (CTLA-
4) immunoglobulin with a high affinity
for both CD80 (B7-1) and CD86 (B7-2).
Although combined bl cking of CD80 
CD86 prevents ligation f CTLA-4 nd
subsequen  T-cell activation, this has lso
inhibited the function of Tregs. Incre sed
risk of post-transplant ly phoproliferative
disorders has been documented.
• CD154: CD40 blockade. Administratio  
of a humanised anti-CD154 mAb in
clinical trials has been c mplicated by the 
development of thromboembolic events.
Immune tolerance remains difficult to achieve
and disruption f a singl pathway is usually
not sufficient to promote tolerance or long-
term allograft survival.
Immunosuppression 
in solid organ 
transplantation
Although immune tolerance is desi d i  
SOT, we s ill rely on immunosuppression 
to vent allograft rejection. Immuno-
suppression has transformed the field of
SOT since agents were first used ov r 50 
years ago, and will still be an essential
c mponent of the armamentarium for the 
foreseeable futu .[13,14]
Most SOT recipients need induction
immunosuppression at the time of
transplantation (usually an intravenous
Co-stimulation MHC: peptide
Anti-T-cell
antibodies
Belatacept
mTOR
Cell cycle
Ca++
TCR
APC
T cell
CYA
Tacrolimus
NFAT
IL-2
transcription
Azathioprine
MMF
Rapamycin
Calcineurin
IL-2
IL-2
receptor
Basiliximab
Daclizumab
Signal 2
Signal 1
Signal 3
i . . t  f  t i i  . i l  i  li  t  t  ll t
 iti  f ti  ti  t  i  t  t t f j  i t ti ilit  l
l l   t  ti ti  ll . i  ti l ti  lt  i  l i i  ti ti , 
 l   l i    t li . ti t  l i i  l t  t  l
f t  f ti t   ll   t t it  t  t  l   i  t  t  i t l i  
t . ti l t  i l  i l    f  ti l   t i ti  i
t   ll. t  ti l ti  i  t   ll t  t  t  ll l   lif t  i l
; t i    l   t  ti i    i , i  i i it  i lli
i   t  li ti .  l i  i  t i , t i i   l t
til i t t  li ti   ll lif ti .   ti ti  ll ; 
 l i  ;   j  i t ti ilit  l ;   l t  til;
  li  t t f i ;   l  f t  f  ti t    ll ;  
ll t . ifi  f  l  t l.[1]
CONTINUING MEDICAL EDUCATION
    November 2014, Vol. 104, No. 11
immunosuppression (usually oral). Almost all immunosuppressive 
drugs are directed against the T cell (Fig. 1)[1,2] for their mechanisms 
of action.
The guiding principle with immunosuppression in SOT is to 
achieve a balance between preventing rejection and avoiding 
side-effects, which include various common and opportunistic 
infections, malignancies, the ‘metabolic syndrome’ group of 
diseases, as well as problems relating to bone structure and 
marrow function. These are beyond the scope of this article and 
are not discussed.
Induction agents
Although not strictly considered part of induction, all patients receive 
high-dose steroids, usually intravenous (IV) methylprednisolone, 
at the time of surgery and for ≥2 days thereafter, depending on the 
graft type and graft function. Most patients should receive induction 
therapy at the time of surgery and for a few days to a week thereafter. 
The most commonly used induction agents are:
• IL-2-receptor blockers. Basiliximab is the only currently
available drug in this class. This anti-CD25 monoclonal antibody
administered on day 0 and day 4 post-transplant, binds CD25 on
the IL-2 receptor of T cells (signal 3 in Fig. 1).
• ATG. This polyclonal antibody preparation (Thymoglobuline/
Fresenius ATG) is prepared by injecting human thymic tissue
into rabbits, and therefore has the potential to cause serum
sickness-like reactions. Being polyclonal, ATG targets multiple
molecules and receptors on thymocytes. ATG is considered the
most potent induction agent for preventing and treating acute
cellular rejection, but also plays a role in preventing antibody-
mediated rejection. It causes prolonged lymphocyte suppression,
increasing the risk of opportunistic infections and post-transplant
lymphoproliferative disease. ATG should therefore be reserved for
patients at highest immunological risk of rejection, such as those
with a high percentage of preformed and, in particular, donor-
specific antibodies.
Maintenance immunosuppression
These drugs are started at the time of transplantation or even before 
in living-related transplants, and are usually lifelong. They can be 
divided into five classes:
• Glucocorticosteroids. Most patients continue oral prednisone
after the initial pulses of IV methylprednisolone. The starting dose 
of 20 - 30 mg daily is tapered to 5 mg daily, or one can alternate
daily over 1 - 3 months, depending on graft function and use of
induction therapy (allows for faster tapering) and other agents used 
in combination. Owing to side-effects, steroids may occasionally
be discontinued, but this increases the risk of rejection and should
be avoided unless mandatory. The side-effects of steroids are well
described and are not different in transplant recipients. Particular
problems include new-onset diabetes after transplantation
(NODAT) and avascular necrosis of the hips. The mechanism
of action of glucocorticosteroids is not fully understood, but the
ability of the intracellular glucocorticoid receptor to alter the
activity of key immune-modulatory transcription factors plays a
key role.
• Anti-metabolites. Azathioprine (AZA) was the first drug in this
class and is still widely used. It was first used as an anti-cancer
drug, and is now widely used in preventing rejection in transplant
recipients and in various autoimmune diseases. It is considered to
be the most ‘safe’ immunosuppressant in pregnancy. Side-effects
include hepatotoxicity and marked bone-marrow suppression
when used with allopurinol (xanthine oxidase interferes with
normal 6-MP breakdown). It is also potentially carcinogenic. The 
starting dose of AZA ranges from 0.5 to 2 mg/kg/day, depending 
on the white cell count, and should be decreased if cytopenias 
occur.
• Mycophenolate mofetil (MMF) or sodium (MPS) is converted
to mycophenolic acid, once absorbed in the gastrointestinal
tract (GIT). Because of lower acute rejection rates and more
predictable dosing, it is replacing AZA in the transplant setting.
Starting doses are MMF 1  g bd or MPS 720  mg bd, but lower
doses may be required depending on the white cell count.
Specific indications include AZA intolerability, rejection on
AZA administration or use of allopurinol. Mycophenolates
commonly have GIT (nausea, ulceration, diarrhoea) and other
side-effects, but these may be less with the enteric-coated
MPS. Mycophenolates are teratogenic and contraindicated in
pregnancy.
• Calcineurin inhibitors (CNIs). Cyclosporin A (CYA) and
tacrolimus (TAC) are the only drugs available in this class. They
form the cornerstone of immunosuppression, around which the
other drugs are added. TAC is a more potent immunosuppressive 
with a slightly different side-effect profile (more risk of
NODAT and neurological side-effects) to CYA (more risk of
hypertension, hyperuricaemia, hirsuitism, gingival hypertrophy 
and hyperlipidaemia). Both are potentially nephrotoxic
(especially cyclosporin) and rarely cause haemolytic-uraemic
syndrome. The once-daily prolonged-release TAC formulation
potentially improves compliance. Monitoring of CNIs is done
using trough levels or a 2-hour concentration (C2) for CYA.
Higher trough levels are targeted early post-transplant (CYA
150 - 300  ng/mL, TAC 8 - 12  ng/mL), and lower levels (CYA
50 - 150 ng/mL, TAC 4 - 10 ng/mL) after 3 - 6 months. Therapy
should however be individualised according to graft type and
graft function.
• Mammalian target of rapamycin inhibitors (mTORi). The 
mTORIs are sirolimus (previously called rapamycin) and
everolimus. mTORIs are not nephrotoxic, but are not as
potent at preventing acute rejection as CNIs. Also called
antiproliferative drugs, they have useful anti-cancer properties, 
and have been used in the treatment of post-transplant
lymphoproliferative disorders (PTLDs) and renal cell
carcinoma. mTORIs are the only class of immunosuppressives
with a decreased risk of cancer. mTORIs delay wound healing
and are not usually used in the peri-transplant period –
everolimus may, however, be combined with low-dose CNI
in this setting. They may need to be stopped around the time
of other major surgery. Other side-effects include stomatitis,
peripheral oedema, hypercholesterolaemia, proteinuria, and
rarely interstitial pneumonitis. About one-third of patients
do not tolerate mTORIs and the main indications for use are
CNI nephrotoxicity and malignancy in a transplant recipient,
especially PTLDs.
• Co-stimulatory inhibitors. The only drug in this class is belatacept 
(CTLA-4-Ig), a CD28 homologue combined with the Fc portion
of IgG3. Being an antibody preparation, it is given IV monthly
lifelong and allows for the omission of CNIs.
The most common immunosuppressive regimens used are 
prednisone with CYA-AZA or TAC-MMF. TAC-MMF is considered 
the more potent combination for preventing rejection, but is 
more expensive and provokes more opportunistic infections, e.g. 
cytomegalovirus (CMV), tuberculosis (TB) and BK virus (polyoma 
virus) nephropathy. 
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CMV prophylaxis with valgancyclovir (3 - 6 months), co-trimox-
azole prophylaxis for Pneumocystis pneumonia (6 months) and TB 
isoniazid prophylaxis (1 year) are routinely used.
In summary, operational tolerance, although desirable, remains 
difficult to achieve in the clinical setting. Tolerance biomarkers may 
help to identify potential transplant recipients who can be weaned 
from maintenance immunosuppression, but this should only be 
attempted with careful monitoring in transplant recipients with stable 
graft function on minimal immunosuppression without histological 
evidence of acute or chronic rejection.
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Transplant definitions
• Allogeneic: From a genetically non-identical donor of the same 
species 
• Types of rejection: Acute rejection is characterised by an
intense cellular and humoral immune attack leading to early
allograft damage and potential graft loss if not controlled.
Chronic rejection is characterised by obliterative vasculopathy
and parenchymal fibrosis leading to allograft loss and is the
main cause of late allograft failure
• Immunosuppression: Inhibition of the normal immune
response to allogeneic antigens that results in rejection of the
allograft
• Tolerance: A state of unresponsiveness to allogeneic antigens in 
the absence of immunosuppression
• Microchimerism: Presence of donor and recipient cell lineages
coexisting within the bone marrow of a myelo-conditioned
recipient
